Avibactam/ceftazidime

Drug Profile

Avibactam/ceftazidime

Alternative Names: AVE 1330/ceftazidime; AVE 1330A/ceftazidime; Avibactam/ceftazidime pentahydrate; AVYCAZ; CAZ 104; CAZ-AVI; Ceftazidime pentahydrate/avibactam; Ceftazidime/AVE 1330; Ceftazidime/AVE 1330A; Ceftazidime/NXL 104; NXL 104/ceftazidime; Zavicefta

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novexel
  • Developer Allergan; AstraZeneca; Cerexa; Novexel; Pfizer
  • Class Amides; Cephalosporins; Heterocyclic bicyclo compounds; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections

Most Recent Events

  • 01 Jun 2017 AstraZeneca completes a phase II trial in Intra-abdominal infections (Combination therapy, In infants, In children, In adolescents) in USA, Argentina, Chile, Czech Republic, Greece, Hungary, Poland, Romania, Russia, Spain, Taiwan and Turkey (NCT02475733)
  • 12 May 2017 Efficacy and adverse events data from the phase III REPROVE trial in Nosocomial pneumonia presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID - 2017)
  • 24 Apr 2017 Efficacy data from the phase III REPROVE-CAZ-AVI presented at the European Congress of Clinical Microbiology and Infectious Disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top